The purpose of the survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about living with and managing castrate resistant prostate cancer (CRPC) from patients and caregivers in order to complete a patient evidence submission for a new medication for non-metastatic castration-resistant prostate cancer called Enzalutamide (Xtandi).
We are looking for input from patients with both metastatic or non-metastatic castration-resistant prostate cancer (mCRPC) and their caregivers. The purpose of this survey is to understand the experience with Enzalutamide (Xtandi) or the need for Enzalutamide to prolong progression from non-metastatic to metastastic disease. If you are a patient outside of this specification and feel you may also benefit from this treatment, we would like to hear from you as well.
The pan-Canadian Oncology Drug Review invites patient groups like CCSN to prepare and send in submissions so that patients and caregivers like you can be heard. Please join us and have your voice included in this important submission process.
The survey only takes about ten minutes to complete, and will remain open until October 3rd, 2018.
Note to Clinicians:
Prostate Cancer Canada (PCC) and the Canadian Cancer Survivor Network (CCSN) would like to invite clinicians to participate in a joint clinician submission to the Canadian Agency for Drugs and Technologies in Health (CADTH) pan-Canadian Oncology Drug Review (pCODR) for the drug enzalutamide (Xtandi) for non-metastatic castration-resistant prostate cancer (nmCRPC).
Providing feedback will take approximately 1-1.5 hours of your time and would need to be completed by Friday, October 5th, 2018. You can find more information about the pCODR process here: https://cadth.ca/pcodr/clinician-input-and-feedback
If you are interested in participating in the joint submission or have any questions about the process, please contact Paulysha De Gannes at Prostate Cancer Canada email@example.com